Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Abstract Background Patients with CML treated with TKI can have a life expectancy comparable to that of the general population. Due to the extended duration of TKI administration, treatment discontinuation has been increasingly sought. Methods Medical records of 100 patients with CML who were in MR4...

Full description

Bibliographic Details
Main Authors: Kamal Chamoun, Hagop Kantarjian, Rami Atallah, Graciela Nogueras Gonzalez, Ghayas C. Issa, Mary Beth Rios, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D. DiNardo, Tapan Kadia, Naveen Pemmaraju, Elias Jabbour, Jorge Cortes
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Journal of Hematology & Oncology
Subjects:
CML
TKI discontinuation
MR4.5
Online Access:http://link.springer.com/article/10.1186/s13045-018-0686-1

Internet

http://link.springer.com/article/10.1186/s13045-018-0686-1

Similar Items